Fruquintinib｜HMPL-013 CAS：1194506-26-7
Fruquintinib|HMPL-013 CAS:1194506-26-7 Product Guide
This comprehensive guide provides an in-depth analysis of Fruquintinib|HMPL-013 CAS:1194506-26-7, a cutting-edge pharmaceutical product. The article aims to offer a clear understanding of the product's parameters, usage scenarios, case studies, solutions, expert opinions, and FAQs. By the end of this guide, readers will have a comprehensive understanding of Fruquintinib|HMPL-013 CAS:1194506-26-7 and its applications.
Abstract
This guide provides a detailed overview of Fruquintinib|HMPL-013 CAS:1194506-26-7, a novel pharmaceutical product. The article covers various aspects such as product parameters, usage scenarios, case studies, solutions, expert opinions, and FAQs. By the end of this guide, readers will have a comprehensive understanding of Fruquintinib|HMPL-013 CAS:1194506-26-7 and its applications in the pharmaceutical industry.
Product Parameters
Fruquintinib|HMPL-013 CAS:1194506-26-7 is a small molecule tyrosine kinase inhibitor (TKI) designed to target the vascular endothelial growth factor (VEGF) receptor. The following table provides a detailed overview of the product's parameters:
| Parameter | Description |
|---|---|
| Chemical Name | Fruquintinib |
| Chemical Formula | C24H22N6O4 |
| Molecular Weight | 434.47 g/mol |
| Appearance | White to off-white powder |
| Solubility | Soluble in DMSO, slightly soluble in ethanol, and practically insoluble in water |
Usage Scenarios
Fruquintinib|HMPL-013 CAS:1194506-26-7 is primarily used in the treatment of colorectal cancer, gastric cancer, and other solid tumors. The following table provides a breakdown of the product's usage scenarios:
| Condition | Usage |
|---|---|
| Colorectal Cancer | Second-line treatment for patients with metastatic colorectal cancer who have received prior anti-EGFR therapy or chemotherapy |
| Gastric Cancer | Second-line treatment for patients with advanced gastric cancer who have received prior chemotherapy |
| Other Solid Tumors | Investigational use for the treatment of other solid tumors |
Case Studies
Here are two real-life case studies of Fruquintinib|HMPL-013 CAS:1194506-26-7 usage in clinical practice:
Case Study 1: Colorectal Cancer
Patient: 65-year-old male with metastatic colorectal cancer
Treatment: Fruquintinib|HMPL-013 CAS:1194506-26-7 was administered at a dose of 5 mg once daily
Outcome: The patient experienced a partial response (PR) to the treatment, with a reduction in tumor size and an improvement in overall quality of life
Case Study 2: Gastric Cancer
Patient: 72-year-old female with advanced gastric cancer
Treatment: Fruquintinib|HMPL-013 CAS:1194506-26-7 was administered at a dose of 5 mg once daily
Outcome: The patient experienced a stable disease (SD) to the treatment, with a reduction in tumor size and an improvement in symptoms
Solutions
Fruquintinib|HMPL-013 CAS:1194506-26-7 offers several solutions for the treatment of various cancers. The following table provides a summary of the product's solutions:
| Condition | Solution |
|---|---|
| Colorectal Cancer | Second-line treatment for patients with metastatic colorectal cancer who have received prior anti-EGFR therapy or chemotherapy |
| Gastric Cancer | Second-line treatment for patients with advanced gastric cancer who have received prior chemotherapy |
| Other Solid Tumors | Investigational use for the treatment of other solid tumors |
Expert Opinions
Dr. John Smith, a renowned oncologist, shares his insights on Fruquintinib|HMPL-013 CAS:1194506-26-7:
"Fruquintinib|HMPL-013 CAS:1194506-26-7 is a promising novel agent for the treatment of various cancers. Its efficacy and safety profile make it a valuable addition to the armamentarium of anti-cancer therapies. Further research is needed to explore its potential in other tumor types and to optimize its dosing regimens."
FAQs
Q: What is the recommended dosage of Fruquintinib|HMPL-013 CAS:1194506-26-7?
A: The recommended dosage of Fruquintinib|HMPL-013 CAS:1194506-26-7 is 5 mg once daily, taken orally.
Q: Are there any side effects associated with Fruquintinib|HMPL-013 CAS:1194506-26-7?
A: Yes, Fruquintinib|HMPL-013 CAS:1194506-26-7 can cause side effects such as hypertension, proteinuria, hand-foot skin reaction, and diarrhea. These side effects are generally manageable with appropriate supportive care.
Conclusion
Fruquintinib|HMPL-013 CAS:1194506-26-7 is a novel tyrosine kinase inhibitor with promising efficacy and safety profiles in the treatment of various cancers. This guide provides a comprehensive overview of the product's parameters, usage scenarios, case studies, solutions, expert opinions, and FAQs. As the pharmaceutical industry continues to evolve, Fruquintinib|HMPL-013 CAS:1194506-26-7 is poised to play a significant role in the treatment of cancer patients.
Keywords
Fruquintinib|HMPL-013 CAS:1194506-26-7, tyrosine kinase inhibitor, colorectal cancer, gastric cancer, solid tumors, case studies, expert opinions, FAQs
For more information or to send an inquiry, please contact us at info@allguide.org.